Sonova Holding stock
SOON.SWSIXSonova Holding AG, HealthcareISIN CH0012549785
74Score 74 out of 100, Strong
Price and trend
80 / 100
Price history
+26% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 29% above it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 44).
The price is 4.9% below its 52-week high. Largest decline in 20 years: 65% (October 2007 to October 2008).
Chart figures for advanced users
- SMA 50$312.08
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$259.48
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)44
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$201.71
- The lowest closing price of the last twelve months.
- Resistance$350.72
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Sonova Holding AG belongs to the Medical (Devices) industry (Switzerland) and, with a market value of $19.82B, is number 12 of 88 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $4.33B (down 0.2% year on year) and earnings of $516.84M (down 20.3%).
- For fiscal 2027, analysts expect on average revenue of $4.67B (up 8%) and adjusted earnings per share of $13.48 (up 23.4%).
Show more
- MEQIRI Score 74 out of 100 (Strong): rank 90 of 702 in Healthcare, median 53.
- The P/E is 39 (Medical (Devices) median 29.1, own median of recent years 25.5).
- Our model puts fair value at $340.75, with the price 2% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Consistently profitableProfit in all 10 fiscal years from 2017 to 2026.Fundamentals 94
- Earnings turn into cashFree cash flow 140% of earnings over the last 12 months.Fundamentals 94
- High return on capitalReturn on invested capital 15.6% in fiscal 2026, Medical (Devices) median 5.4%.Profitability 76
Weaknesses
- Richly valuedP/E 39, Medical (Devices) median 29.1, own median 25.5.Valuation 40
Its standout strengths are fundamentals and stability, while growth and valuation hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among stocks ranked 101 to 1,000.
From 2016 to 2025, 9 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What lowers it
- solid fundamentals
- price near its 52-week high
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $262.12 and expensive above $486.79 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $432.77 (cash-flow model) and $248.74 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 5.6%. At 6.6% the fair value would be $302.43, at 4.6% it would be $398.43.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (29.1).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2026, revenue fell 0.2% on the prior year. Revenue has grown solidly since 2007, at about 7% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 74%, operating 19%, net not measured.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 18 May 2027in 186 days
- Last reported
- 12 Nov 2026EPS reported $6.17 (expected $5.28)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $13.48+1.6%
- Revenue
- $4.67B0.0%
- Earnings per share
- $15.10+1.9%
- Revenue
- $5.01B0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +11.7%First outlook for fiscal 2026-27: sales up 5% to 8% and core EBIT up 7% to 10% at constant exchange rates, with performance expected to improve in the second half.
“In summary, we expect consolidated sales to rise 5% to 8% and core EBIT to grow 7% to 10% at constant exchange rates.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 18 May 2026 (fiscal Q4 2026), read by AI.
What happened at Sonova Holding
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 74
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- Shenzhen Mindray Bio-Medical Electronics300760.SZ $32.26B74
- DexComDXCM $30.35B79
- Koninklijke PhilipsPHIA.AS $29.52B56
- Terumo4543.T $23.63B76
- Zimmer Biomet HoldingsZBH $19.79B68
- GlaukosGKOS $14.56B48
- Smith & NephewSNN $12.97B67
- PenumbraPEN $12.64B58
ETFs that hold Sonova Holding
Held by 113 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares MSCI Europe Quality Dividend Advanced UCITS ETFQDVX | 1.42% | 0.28% | €959.8M |
| iShares SLI UCITS ETF (DE)EXI1 | 1.38% | 0.51% | €589.04M |
| Amundi DJ Switzerland Titans 30 UCITS ETF DistC030 | 1.01% | 0.25% | €239.17M |
Show 5 more
| Amundi MSCI Europe Ex EMU ESG Selection UCITS ETF Acc540H | 0.94% | 0.30% | €183.15M |
| iShares STOXX Europe Mid 200 UCITS ETF (DE)EXSD | 0.93% | 0.20% | €634.13M |
| iShares MSCI World Health Care Sector Advanced UCITS ETFCBUF | 0.89% | 0.18% | €839.61M |
| Xtrackers MSCI Europe Health Care Screened UCITS ETF 1CDXSE | 0.88% | 0.17% | €362.64M |
| iShares MSCI Europe Health Care Sector UCITS ETFESIH | 0.88% | 0.18% | €953.22M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CHF 0.8331)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.